Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vericel Corporation (NQ: VCEL )

46.42 +1.04 (+2.29%)
Official Closing Price Updated: 4:15 PM EDT, Apr 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 362,327
Open 45.59
Bid (Size) 44.27 (1)
Ask (Size) 52.34 (7)
Prev. Close 45.38
Today's Range 45.42 - 47.14
52wk Range 29.23 - 53.05
Shares Outstanding 46,631,158
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Analyst Scoreboard: 5 Ratings For Vericel
Via Benzinga
It's A Bull Market But Harder To Pick Small Cap Biotech Winners Because Of Volatility
Biotech is in a bull market aș measured by 2023 trends with a double testing of lows on 11/23. 
Via Talk Markets

Performance

YTD
+33.08%
+33.08%
1 Month
-3.17%
-3.17%
3 Month
+9.87%
+9.87%
6 Month
+31.02%
+31.02%
1 Year
+53.76%
+53.76%

More News

Read More
A Closer Look at 4 Analyst Recommendations For Vericel
Via Benzinga
Vericel Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Full-Year 2024 Financial Guidance
From Vericel Corporation
Via GlobeNewswire
Earnings Scheduled For February 29, 2024
Via Benzinga
Vericel to Present at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024
From Vericel Corporation
Via GlobeNewswire
HC Wainwright & Co. Maintains Buy Rating for Vericel: Here's What You Need To Know
Via Benzinga
Analyst Ratings for Vericel
Via Benzinga
3 Top Pharma Stocks for Investors Betting on a Biotech Boom
Via InvestorPlace
Vericel to Report Fourth-Quarter and Full-Year 2023 Financial Results on February 29, 2024
From Vericel Corporation
Via GlobeNewswire
5 medical stocks growing earnings by triple digits
Via MarketBeat
Topics Economy
Exposures Economy
Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Monday, February 12, 2024
From Vericel Corporation
Via GlobeNewswire
Analyst Ratings for Vericel
Via Benzinga
Vericel Corp. (NASDAQ: VCEL) Sets New 52-Week High in Tuesday Session
Via Investor Brand Network
Vericel Announces Preliminary Full-Year and Fourth Quarter 2023 Financial Results
From Vericel Corporation
Via GlobeNewswire
Vericel to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024
From Vericel Corporation
Via GlobeNewswire
Innovative Burn Care: MediWound Bags Additional DoD Grant For NexoBrid Development
Via Benzinga
3 Biotech Stocks That Could Boom or Bust by 2025
Via InvestorPlace
3 Strong Buy Stocks Set to Take Off in the Coming Months
Via InvestorPlace
Vericel Reports Third Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance
From Vericel Corporation
Via GlobeNewswire
Vericel to Present at the Stephens Annual Investment Conference
From Vericel Corporation
Via GlobeNewswire
Earnings Scheduled For November 8, 2023
Via Benzinga
Vericel to Report Third-Quarter 2023 Financial Results on November 8, 2023
From Vericel Corporation
Via GlobeNewswire
Vericel Announces Publication of Positive Results from Phase 3 Debride and Protect (DETECT) Study of Thermal Burn Patients Treated with NexoBrid
From Vericel Corporation
Via GlobeNewswire
Vericel Announces U.S. Commercial Availability of NexoBrid® (anacaulase-bcdb) for the Treatment of Severe Thermal Burns in Adults
From Vericel Corporation
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.